Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved.
作者信息
Dahari Harel, Guedj Jeremie, Perelson Alan S
出版信息
Hepatology. 2011 Aug;54(2):749. doi: 10.1002/hep.24310. Epub 2011 Jun 27.
Abstract
摘要
相似文献
1
Silibinin mode of action against hepatitis C virus: a controversy yet to be resolved.
Hepatology. 2011 Aug;54(2):749. doi: 10.1002/hep.24310. Epub 2011 Jun 27.
2
Silymarin for HCV infection.
Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25.
3
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
PLoS One. 2011 Jan 28;6(1):e16464. doi: 10.1371/journal.pone.0016464.
4
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B.
Hepatology. 2013 Mar;57(3):953-63. doi: 10.1002/hep.26260. Epub 2013 Feb 7.
5
Phytoliposome-Based Silibinin Delivery System as a Promising Strategy to Prevent Hepatitis C Virus Infection.
J Biomed Nanotechnol. 2016 Apr;12(4):770-80. doi: 10.1166/jbn.2016.2161.
6
Silibinin: an old drug in the high tech era of liver transplantation.
J Hepatol. 2013 Mar;58(3):409-11. doi: 10.1016/j.jhep.2012.11.030. Epub 2012 Nov 27.
7
Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
J Clin Pharmacol. 2010 Apr;50(4):434-49. doi: 10.1177/0091270009347475. Epub 2009 Oct 19.
8
Hepatitis C viral kinetics: the past, present, and future.
Clin Liver Dis. 2013 Feb;17(1):13-26. doi: 10.1016/j.cld.2012.09.003.
9
Prostate cancer prevention by silibinin.
Curr Cancer Drug Targets. 2004 Feb;4(1):1-11. doi: 10.2174/1568009043481605.
10
Highly bioavailable silibinin nanoparticles inhibit HCV infection.
Gut. 2017 Oct;66(10):1853-1861. doi: 10.1136/gutjnl-2016-312019. Epub 2016 Jul 19.
引用本文的文献
1
Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.
Front Microbiol. 2019 Jan 8;9:3257. doi: 10.3389/fmicb.2018.03257. eCollection 2018.
2
Silibinin Induced Human Glioblastoma Cell Apoptosis Concomitant with Autophagy through Simultaneous Inhibition of mTOR and YAP.
Biomed Res Int. 2018 Mar 26;2018:6165192. doi: 10.1155/2018/6165192. eCollection 2018.
3
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.
Liver Int. 2015 Feb;35(2):289-94. doi: 10.1111/liv.12692. Epub 2014 Oct 10.
4
A hepatitis C virus infection model with time-varying drug effectiveness: solution and analysis.
PLoS Comput Biol. 2014 Aug 7;10(8):e1003769. doi: 10.1371/journal.pcbi.1003769. eCollection 2014 Aug.
5
Inhibition of RNA binding to hepatitis C virus RNA-dependent RNA polymerase: a new mechanism for antiviral intervention.
Nucleic Acids Res. 2014 Aug;42(14):9399-409. doi: 10.1093/nar/gku632. Epub 2014 Jul 22.
6
Silymarin for HCV infection.
Antivir Ther. 2013;18(2):141-7. doi: 10.3851/IMP2402. Epub 2012 Sep 25.
7
Understanding silibinin's modes of action against HCV using viral kinetic modeling.
J Hepatol. 2012 May;56(5):1019-1024. doi: 10.1016/j.jhep.2011.12.012. Epub 2012 Jan 13.
本文引用的文献
1
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation.
PLoS One. 2011 Jan 28;6(1):e16464. doi: 10.1371/journal.pone.0016464.
2
RG7128 alone or in combination with pegylated interferon-α2a and ribavirin prevents hepatitis C virus (HCV) Replication and selection of resistant variants in HCV-infected patients.
J Infect Dis. 2010 Nov 15;202(10):1510-9. doi: 10.1086/656774. Epub 2010 Oct 13.
3
A perspective on modelling hepatitis C virus infection.
J Viral Hepat. 2010 Dec;17(12):825-33. doi: 10.1111/j.1365-2893.2010.01348.x. Epub 2010 Aug 15.
4
Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV-HCV coinfected patient.
J Clin Virol. 2010 Oct;49(2):131-3. doi: 10.1016/j.jcv.2010.07.006. Epub 2010 Aug 14.
5
Multiple effects of silymarin on the hepatitis C virus lifecycle.
Hepatology. 2010 Jun;51(6):1912-21. doi: 10.1002/hep.23587.
6
Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase.
Gastroenterology. 2010 Mar;138(3):1112-22. doi: 10.1053/j.gastro.2009.11.053. Epub 2009 Dec 4.
7
Rapid suppression of hepatitis C viremia induced by intravenous silibinin plus ribavirin.
Gastroenterology. 2009 Jul;137(1):390-1. doi: 10.1053/j.gastro.2009.02.087. Epub 2009 May 30.
8
Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy.
Gastroenterology. 2008 Nov;135(5):1561-7. doi: 10.1053/j.gastro.2008.07.072. Epub 2008 Aug 3.
9
Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy.
Science. 1998 Oct 2;282(5386):103-7. doi: 10.1126/science.282.5386.103.
Zotero 插件